Adults who are overweight or obese and currently using semaglutide (Ozempic®/Wegovy®) or tirzepatide (Mounjaro®/Zepbound®) may qualify for a research study evaluating an investigational weight loss medication.
Obesity Study
Age Range:
18
Gender:
Male and Female
Location:
Rochester, New York
About the Study
This research study is evaluating maridebart cafraglutide, an investigational medication designed to help maintain weight loss in adults who have previously responded to GLP-1 treatment. The study medication is given as an injection using a prefilled syringe.
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of switching from a currently prescribed GLP-1 medication to the investigational study medication.
Qualifications
You may be able to join if you:
- Are 18 years of age or older
- Have a BMI greater than 25 kg/m²
- Have used semaglutide or tirzepatide consistently for at least 6 months
- Have maintained a stable dose of your medication for at least 6 months
- Have lost at least 10% of your body weight while using semaglutide or tirzepatide
- Have had stable body weight over the past 6 months
FEATURED STUDIES
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]
Adults 18 and older who have had daily moderate to severe low back pain for at least 3 months may […]
Adults living with obesity, or overweight with a weight-related health condition, may qualify for a clinical research study evaluating an […]
Adults 18 years and older with overweight or obesity and without type 2 diabetes may qualify for a study evaluating […]
Adults with osteoarthritis (OA) knee pain may qualify for a research study evaluating an investigational medication for chronic pain relief.
Adults 18 to 75 years of age may qualify for a research study evaluating an investigational medication for migraine attacks.